WO2013071456A3 - Microparticles comprising a polylactic- glycolic polymer and an antimicrobial agent selected from ceftiofur or florfenicol - Google Patents

Microparticles comprising a polylactic- glycolic polymer and an antimicrobial agent selected from ceftiofur or florfenicol Download PDF

Info

Publication number
WO2013071456A3
WO2013071456A3 PCT/CL2012/000066 CL2012000066W WO2013071456A3 WO 2013071456 A3 WO2013071456 A3 WO 2013071456A3 CL 2012000066 W CL2012000066 W CL 2012000066W WO 2013071456 A3 WO2013071456 A3 WO 2013071456A3
Authority
WO
WIPO (PCT)
Prior art keywords
lacticcoglycolic
ceftiofur
florfenicol
plga
preparation
Prior art date
Application number
PCT/CL2012/000066
Other languages
English (en)
French (fr)
Other versions
WO2013071456A2 (es
Inventor
Cristian VILOS ORTIZ
Luis VELASQUEZ CUMPLIDO
Pedro ORIHUELA DIAZ
Miguel RIOS RAMIREZ
Original Assignee
Universidad De Santiago De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Santiago De Chile filed Critical Universidad De Santiago De Chile
Publication of WO2013071456A2 publication Critical patent/WO2013071456A2/es
Publication of WO2013071456A3 publication Critical patent/WO2013071456A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición veterinaria inyectable de liberación prolongada que comprende micropartículas que contienen un polímero biodegradable biocompatible seleccionado de ácido poliláctico-glicólico (PLGA), que encapsula un agente antimicrobiano seleccionado de Ceftiofur o Florfenicol o una mezcla de los mismos y procedimiento de preparación.
PCT/CL2012/000066 2011-11-18 2012-11-15 Composición veterinaria inyectable de liberación prolongada de ceftiofur y florfenicol en especies animales que comprende micropartículas de acido poliláctico-glicólico (plga) y procedimiento de preparación WO2013071456A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2902-2011 2011-11-18
CL2011002902A CL2011002902A1 (es) 2011-11-18 2011-11-18 Composicion veterinaria inyectable de liberacion prolongada que comprende microparticulas que comprenden polimero acido polilactico-glicolico (plga) y un agente antimicrobiano seleccionado de ceftiofur o florfenicol o una mezcla de ellos; procedimiento de preparacion, util para tratar infecciones en animales.

Publications (2)

Publication Number Publication Date
WO2013071456A2 WO2013071456A2 (es) 2013-05-23
WO2013071456A3 true WO2013071456A3 (es) 2013-08-01

Family

ID=47556986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CL2012/000066 WO2013071456A2 (es) 2011-11-18 2012-11-15 Composición veterinaria inyectable de liberación prolongada de ceftiofur y florfenicol en especies animales que comprende micropartículas de acido poliláctico-glicólico (plga) y procedimiento de preparación

Country Status (2)

Country Link
CL (1) CL2011002902A1 (es)
WO (1) WO2013071456A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113288876B (zh) * 2021-03-25 2022-09-27 华南农业大学 一种氟苯尼考缓释颗粒的质量评价与控制方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1843330A (zh) * 2006-05-24 2006-10-11 山东蓝金生物工程有限公司 一种含氨基糖苷类抗菌素的缓释剂及其应用
CN1850044A (zh) * 2006-05-17 2006-10-25 济南帅华医药科技有限公司 一种含氨基糖苷类抗菌素的缓释注射剂及其应用
CN101756910A (zh) * 2010-03-18 2010-06-30 青岛康地恩药业有限公司 一种肺靶向头孢噻呋微球及制备方法
CN101773478A (zh) * 2010-03-22 2010-07-14 青岛康地恩药业有限公司 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850044A (zh) * 2006-05-17 2006-10-25 济南帅华医药科技有限公司 一种含氨基糖苷类抗菌素的缓释注射剂及其应用
CN1843330A (zh) * 2006-05-24 2006-10-11 山东蓝金生物工程有限公司 一种含氨基糖苷类抗菌素的缓释剂及其应用
CN101756910A (zh) * 2010-03-18 2010-06-30 青岛康地恩药业有限公司 一种肺靶向头孢噻呋微球及制备方法
CN101773478A (zh) * 2010-03-22 2010-07-14 青岛康地恩药业有限公司 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法

Also Published As

Publication number Publication date
WO2013071456A2 (es) 2013-05-23
CL2011002902A1 (es) 2012-07-06

Similar Documents

Publication Publication Date Title
MX2016012846A (es) Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.
PH12014502340A1 (en) A delayed release drug formulation
MY169349A (en) Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds
WO2010125475A3 (en) Sustained release formulations comprising gnrh analogues
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
MY164607A (en) Solid compositions
BR112012004216A2 (pt) "estereocomplexo de ácido poliláctico, método para produzir um estereocomplexo de ácido poliláctico, agente nucleante para resina de ácido poliláctico, método para produzir um composição de resina de ácido poliláctico e produto moldado"
IN2012DN00570A (es)
WO2011089595A3 (en) Sustained-release nucleic acid matrix compositions
BRPI1011188A2 (pt) composições de liberação dérmica compreendendo complexos de partículas de agente ativo-fosfato de cálcio e métodos para usar as mesmas.
CL2008003092A1 (es) Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .
EP2592146A3 (en) Methods and compositions for treating prostate cancer
MX311193B (es) Composicion para exterminar parasitos de animales, y metodo para exterminar parasitos de animales.
MX2014006601A (es) Formulaciones de moxidectina inyectables de larga accion y formas de cristal de moxidectina novedosas.
UA117260C2 (uk) Лікарський препарат з відстроченим вивільненням
BR112013011967A2 (pt) composição biodegradável para distribuição de fármaco
EP2719714A4 (en) LACTID COPOLYMER, METHOD FOR ITS PREPARATION AND RESIN COMPOSITION THEREWITH
WO2010085609A3 (en) Controlled release systems from polymer blends
WO2013013038A3 (en) Doping agents and polymeric compositions thereof for controlled drug delivery
BR112012001997A2 (pt) Formulação revestida, aditivo para alimentação, alimentação, e, métodos de criar um animal doméstico, e de fabricar uma formulação revestida.
PH12013000124A1 (en) Pharmaceutical microsphere for embolization
HK1141451A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
EP3275431A4 (en) System for homogenization of drug in biodegradable polymer: smart polymeric system
WO2013071456A3 (es) Microparticles comprising a polylactic- glycolic polymer and an antimicrobial agent selected from ceftiofur or florfenicol
PH12018500304A1 (en) A delyade release drug formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12813737

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12813737

Country of ref document: EP

Kind code of ref document: A2